The impact of clopidogrel on plasma-soluble CD40 ligand levels in systemic lupus erythematosus patients: the CLOPUS phase I/II pilot study - 06/03/21

Guillaume Vial ^a, ⁎, 1

  These authors contributed equally to this work.

, Noémie Gensous ^a, 1

  These authors contributed equally to this work.

, Hélène Savel ^c, Christophe Richez ^{b, d}, Estibaliz Lazaro ^{b, e}, Marie-Elise Truchetet ^{b, d}, Fabrice Bonnet ^f, Isabelle Pellegrin ^g, Rodolphe Thiebaut ^h, Patrick Blanco ^g, Pierre Duffau ^{a, b,} 1

  These authors contributed equally to this work.

^a Department of Internal Medicine and Clinical Immunology, Saint Andre Hospital, University Hospital Centre of Bordeaux, 33000 Bordeaux, France 

^b CNRS UMR 5164, Immuno ConcEpT, Bordeaux University, 33076 Bordeaux, France 

^c Methodological Support Unit for Clinical Research, University Hospital Centre of Bordeaux, 33000 Bordeaux, France 

^d Department of Rheumatology, Pellegrin Hospital, University Hospital Centre of Bordeaux, 33000 Bordeaux, France 

^e Department of Internal Medicine and Infectious Diseases, Haut Leveque Hospital, University Hospital Centre of Bordeaux, 33604 Pessac, France 

^f Department of Internal Medicine and Infectious Diseases, Saint Andre Hospital, University Hospital Centre of Bordeaux, 33000 Bordeaux, France 

^g Department of Immunology and Immunogenetics, Pellegrin Hospital, University Hospital Centre of Bordeaux, 33000 Bordeaux, France 

^h Department of Public Health, University Hospital Centre of Bordeaux, 33000 Bordeaux, France 

^⁎Corresponding author at: Saint-Andre Hospital, 1, rue Jean Burguet, 33000 Bordeaux, France.Saint-Andre Hospital1, rue Jean BurguetBordeaux33000France